| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 47(4); 2015 > Article
Lee, Lee, Kim, Lee, Kim, Lee, Kim, and Heo: Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer



Cisplatin-associated arterial and venous thromboembolic events (TEEs) are becoming an increasing concern. In patients with small-cell lung cancer (SCLC) who are treated using cisplatin-based chemotherapy, we assume that the overall risk of TEEs is high. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. The aim of this study was to determine the incidence of TEEs in patients with SCLC and to analyze the predictors for TEE occurrence.

Materials and Methods

We retrospectively analyzed 277 patients who received chemotherapy for SCLC between 2006 and 2012. As the influence of chemotherapy on TEE occurrence developed after its initiation, a time-dependent Cox regression analysis was used to estimate the significant predictors for TEE.


Among the 277 patients, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of 30 total TEEs, 22 (73%) occurred between the time of initiation and 4 weeks after the last dose of platinum-based chemotherapy. Approximately 218 patients (79%) received cisplatin-based chemotherapy. In multivariate analysis, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (hazard ratio [HR], 4.36; p=0.05). Variables including smoking status (common HR, 2.14; p=0.01) and comorbidity index (common HR, 1.60; p=0.05) also showed significant association with TEE occurrence.


The 1-year cumulative incidence of TEE is 10.2% in Asian patients with SCLC. Cisplatin-based chemotherapy in SCLC might be a strong predictor for the risk of TEE.


Patients with malignancy have a 4- to 8-fold increased risk of venous thromboembolism compared to those without malignancy [1,2]. The risk of thrombosis varies according to the site of the cancer, tumor burden at diagnosis, and cancer-related treatment [3,4].
Among chemotherapeutic agents, cisplatin in particular has been associated with an increased risk of a thromboembolic event (TEE) [5-8]. In a recent study by Moore et al. [7] including 932 patients with solid malignancies receiving cisplatin-based chemotherapy, 18% of the patients experienced a TEE. Therefore, we can assume that the risk of TEE is considerable in patients with small-cell lung cancer (SCLC); cisplatin in combination with etoposide or irinotecan is the most commonly used regimen [9,10]. However, cisplatin-associated vascular toxicity in patients with SCLC has been overlooked to date. In addition, no studies primarily evaluating the risk of TEE in patients with SCLC have been reported.
The aim of the current study was to investigate the incidence and characteristics of TEE in patients with SCLC who received platinum-based chemotherapy.

Materials and Methods

1. Patient population

All patients who received chemotherapy for SCLC and underwent at least 4 weeks of follow-up after their initial chemotherapy session between January 2006 and June 2012 were analyzed retrospectively. This study was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. H-1102-013-349).
Comorbidity was assessed using the Adult Comorbidity Evaluation 27 (ACE-27), a validated comorbidity instrument used for assessment of patients with cancer [11]. Grades were assigned according to the severity of an individual’s organ decompensation and its prognostic impact. We calculated the Khorana risk score for prediction of chemotherapy-associated thromboembolism using the body mass index (BMI), hemoglobin level, and platelet and white blood cell counts [12]. SCLC stages were classified as either limited or extensive, with the limited-stage confined to the primary tumor and its regional nodal involvement. Treatment characteristics were also collected, including the treatment strategy, chemotherapy regimen, exposure to cisplatin, number of cisplatin cycles, and cumulative cisplatin dose.

2. Identification of TEE

We defined TEE to include arterial thrombosis, deep vein thrombosis (DVT), pulmonary embolism (PE), and thrombosis in other vascular territories except for superficial vein. All reports of radiological (computerized tomography [CT], CT angiography, Doppler ultrasonography, and conventional angiography) or nuclear medicine (ventilation/perfusion scans) studies were reviewed in order to identify a venous or arterial TEE. Two independent investigators (Y.-G.L. and E.L.) double-checked and confirmed the occurrence of TEE by retrospective review of electrical medical records and results of imaging studies. Two or more TEEs occurring either simultaneously or at different times were counted as one event.

3. Statistical analyses

The primary study objective was to determine the cumulative incidence and characteristics of TEEs in patients with SCLC. The time-to-TEE was calculated by taking the difference in time from the date of cancer diagnosis to the first identified date of TEE occurrence. The cumulative hazard estimates for TEE were calculated using the Nelson-Aalen method and compared between groups using log-rank tests. The secondary study objective was to investigate the predictive risk factors for the occurrence of a TEE, which was analyzed using Cox time-dependent covariate regression analysis. When a linear effect of a categorical variable was suspected, we calculated the common hazard ratio (HR) from one group to the next. Variables that were found to be significant with p ≤ 0.05 using a stepwise backward-selection method were entered into a final multivariate model. All analyses were performed using Stata ver. 12.0 (StataCorp, College Station, TX).


1. Baseline and treatment characteristics of the study population

Overall, 306 patients were diagnosed with SCLC during the study period; 277 received chemotherapy and were included in the current study. Twenty-nine patients were excluded; 26 patients did not receive chemotherapy due to old age and/or poor performance status, and three patients were found to have a TEE at the time of cancer diagnosis.
Patients’ baseline and treatment characteristics are summarized in Tables 1 and 2, respectively. The Khorana risk score is included in Table 1. Of the total 277 patients, eight (3%) had experienced cerebrovascular events and 14 (5%) had experienced coronary artery disease including either angina or myocardial infarction. None had experienced both cerebrovascular events and coronary heart disease. With regard to the first-line chemotherapy, 206 patients (74%) received a cisplatin-based regimen and 71 (26%) received a carboplatin-based regimen. Of these 71 patients, 11 (16%) were treated with a cisplatin-based regimen as second-line chemotherapy. In comparison of the baseline characteristics after the first-line chemotherapy, patients receiving an initial carboplatin-based regimen had a poorer performance status (p=0.009) and more severe organ decompensation (p < 0.001) compared to those receiving an initial cisplatin-based regimen.

2. Incidence, timing and characteristics of TEE development

Among the 277 patients included in this study, 30 patients (11%) developed a TEE. The 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. Of a total of 30 TEEs, all TEEs occurred in patients who had received a platinum-based chemotherapy; 22 (73%) occurred between the time of initiation and four weeks after the last dose of platinum-based chemotherapy and the remaining eight (27%) occurred during best supportive care after the end of chemotherapy. Among 22 TEEs associated with platinum-based chemotherapy, 20 (91%) occurred during cisplatin-based chemotherapy and two (9%) occurred during carboplatin-based chemotherapy. Among 20 TEEs related to the cisplatin-based chemotherapy, the majority (90%) occurred during the first-line cisplatin chemotherapy (between the time of initial dose of chemotherapy and 4 weeks after the last dose) and the other 10% occurred thereafter. Fig. 1 shows the cumulative incidence of TEEs after first-line chemotherapy. Overall, the median time from the time of cancer diagnosis until TEE occurrence was 132 days (interquartile range, 58 to 394 days).
The majority of events were the occurrence of only PE (n=15), followed by arterial thrombosis (cerebrovascular accidents+central arterial thrombosis, n=7), DVT combined with PE (n=4), and only DVT (n=4).

3. Univariate and multivariate analyses of baseline and treatment characteristics

In univariate analyses, the smoking status (current vs. non-smoker), stage of SCLC, and invasion of the superior vena cava showed association with a significant increase in the risk of TEE (Table 1). Previous history of major vascular events (cerebrovascular events or coronary artery disease) was not associated with TEE occurrence (unpublished data). The study concluded that among the predictive variables included in the Khorana risk model, none showed significant association with TEE occurrence. The overall Khorana risk score was also not predictive of TEE occurrence. In analysis of the data by treatment variables, radiotherapy did not show association with TEE occurrence. Cisplatin-based chemotherapy showed association with increased risk of TEE, which was marginally significant (HR, 3.66; 95% confidence interval [CI], 0.87 to 15.43; p=0.08). However, median dose of cisplatin did not show correlation with the TEE (p=0.20).
In multivariate analysis that included treatment variables as time-dependent covariates, cisplatin-based chemotherapy was an independent risk factor for TEE occurrence (HR, 4.36; 95% CI, 1.00 to 18.97; p=0.05). Variables including the smoking status (common HR, 2.14; 95% CI, 1.16 to 3.95; p=0.01) and ACE-27 comorbidity (common HR, 1.60; 95% CI, 1.00 to 2.58; p=0.05) also showed significant association with TEE occurrence (Table 3).


This is the first study to focus primarily on SCLC and to evaluate the risk of TEE in patients with SCLC. In our retrospective analysis of 277 patients treated with platinum-based chemotherapy for SCLC, the 3-month, 6-month, and 1-year cumulative incidences of TEEs were 5.0%, 9.1%, and 10.2%, respectively. In multivariate analysis, the current smoking status, higher comorbidity index, and cisplatin-based chemotherapy were independent predictors for increased risk of TEE. Compared to patients receiving non-cisplatin based chemotherapy, risk of TEE was 4.4 times higher for patients receiving cisplatin-based chemotherapy.
In a population-based study including 13,542 patients with SCLC conducted in California between 1993 and 1999, the 2-year incidence of venous thromboembolism in patients with SCLC was 2.5% [13]. Given the low incidence reported in the Western epidemiologic study, our result showing a 1-year cumulative incidence of 10.2% seems high. However, in recent studies focusing on the relationship between cisplatin and thromboembolism, the incidence of TEE was 8.4% to 12.9% in patients primarily receiving cisplatin-containing chemotherapy [5,14]. A recent retrospective study analyzing 932 patients treated with cisplatin-based chemotherapy for various cancers also reported a similar incidence of TEEs (11.8%) in 204 patients with lung cancer [7]. In our study, almost 80% of patients were exposed to cisplatin-based chemotherapy. In addition, the risk of TEE in patients receiving cisplatin-based chemotherapy was 4.4 times higher than that of those receiving non-cisplatin based chemotherapy. The results of the current study support the hypothesis that cisplatin-based chemotherapy was indeed a major contributor to the high incidence rates of TEE.
Despite clinical evidence of cisplatin-induced hypercoagulability, the pathophysiology remains unclear. Several studies have suggested that cisplatin may cause the following actions: endothelial damage via induction of procoagulant microparticles, an increase in the procoagulant activity of red blood cells, and modulation of tissue factor on human monocytes. These characteristics may contribute to cisplatin-induced hypercoagulability [15-18].
In terms of dose-response relationship, according to our data, the cumulative dose of cisplatin did not show correlation with TEE occurrence. This finding is consistent with results from a previous large retrospective study by Moore et al. [7], however, a recent meta-analysis suggested that the higher dose of cisplatin was associated with the heightened risk of thromboembolism [8]. These conflicting results can be explained in part by the study design (retrospective vs. prospective) and the size of the study. Therefore, conduct of well-designed and prospective studies is warranted.
In contrast to the well-known risk factors (smoking status, comorbidity index, and cisplatin-based chemotherapy) for thrombosis in our study, the Khorana score was not predictive of development of TEE. This finding may be explained by the fact that the overall risks for TEE in patients receiving cisplatin-containing chemotherapy were much higher compared to those in the study population included in the Khorana study [12]. The very low proportion of patients with a BMI ≥ 35 kg/m2 in this study in comparison with the Khorana study (0.4% vs. 12.3%) also contributes to the lack of predictive significance of the Khorana variables. Given the difference in cut-off points of BMI as an indicator of obesity between Asians and Caucasians, an area-specific cut-off point for BMI among the Khorana variables should be taken into consideration.
Our results are limited by selection bias due to the retrospective nature of the study. The exclusion of patients who did not receive chemotherapy because of poor performance status and/or severe organ decompensation may lead to an underestimation of the real burden of TEE in patients with SCLC. Since the total number of patients with SCLC and TEE is low due to their rare incidence, our analyses were most likely underpowered for detection of statistical significance. Therefore, conduct of additional studies with large sample sizes will be necessary in order to confirm our findings.


In conclusion, in the current study, the 3-month, 6-month, and 1-year cumulative incidences of TEEs in Asian patients with SCLC were 5.0%, 9.1%, and 10.2%, respectively. Cisplatin-based chemotherapy in SCLC might be a strong predictor for the risk of TEE.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.


This study was supported by grant No. 0720142084 from the National Research Foundation of Korea and by a grant of Seoul National University College of Medicine (800-20140171). The authors wish to thank Leo Song (University College Dublin School of Medicine, Dublin, Ireland) for the assistance in data collection.

Fig. 1.
Cumulative incidence of thromboembolic events (TEEs) according to chemotherapeutic regimen. HR, hazard ratio.
Table 1.
Baseline characteristics and univariate analysis for development of thromboembolic events (TEEs)
Characteristic Patient TEE case Hazard ratio p-value
Total patients 277 (100) 3010.8) - -
Age group (yr)
 < 65 123 (44.4) 15 (12.2) 1
 ≥ 65 154 (55.6) 15 (9.7) 0.97 (0.47-1.99) 0.94
 Male 247 (89.2) 26 (10.5) 1
 Female 30 (10.8) 4 (13.3) 1.27 (0.44-3.64) 0.66
ECOG performance status
 0-1 250 (90.3) 26 (10.4) 1
 2-3 27 (9.7) 4 (14.8) 2.33 (0.81-6.75) 0.12
Smoking status
 Never smoker 80 (28.9) 2 (2.5) 1
 Ex-smoker 43 (15.5) 4 (9.3) 3.77 (0.69-20.63) 0.13
 Current smoker 154 (55.6) 24 (15.6) 6.03 (1.43-25.54) 0.02
ACE-27 comorbidity index
 No comorbidity 124 (44.8) 14 (11.3) 1
 Mild decompensation 117 (42.2) 119.4) 0.95 (0.43-2.10) 0.9
 Moderate decompensation 27 (9.8) 3 (11.1) 1.44 (0.41-5.03) 0.57
 Severe decompensation 9 (3.3) 2 (22.2) 3.09 (0.70-13.61) 0.14
Khorana variable 42 (15.2) 2 (4.8) 0.45 (0.11-1.91) 0.28
 Prechemotherapy platelet count (≥ 350×109/L)
 Prechemotherapy hemoglobin (< 10 g/dL or use of ESA) 6 (2.2) 0 - -
 Prechemotherapy leukocyte count (> 11×109/L) 36 (13) 2 (5.6) 0.65 (0.15-2.74) 0.56
BMI ≥ 35 kg/m2 1(0.4) 0 - -
Khorana risk score
 1 205 (74) 27 (13.2) 1
 2 60 (21.7) 2 (3.3) 0.30 (0.07-1.25) 0.1
 3 11 (4) 19.1) 0.96 (0.13-7.11) 0.97
 4 1 (0.4) 0 - -
Khorana risk group
 Intermediate 265 (95.7) 29 (10.9) 1
 High 12 (4.3) 18.3) 1.04 (0.14-7.68) 0.97
 Limited 103 (37.2) 9 (8.7) 1
 Extensive 174 (62.8) 2112.1) 2.20 (0.99-4.90) 0.05
Superior vena cava invasion
 No 252 (91) 24 (9.5) 1
 Yes 25 (9) 6 (24) 2.75 (1.12-6.74) 0.03

ECOG, Eastern Cooperative Oncology Group; ACE, Adult Comorbidity Evaluation; ESA, erythropoiesis-stimulating agent; BMI, body mass index.

Table 2.
Treatment outcomesl
Characteristic No. (%)
Initial treatment
 Chemotherapy 211 (76.2)
 Chemotherapy+radiation therapy 38 (13.7)
 Radiation followed by chemotherapy 28 (10.1)
First-line chemotherapy (n=277)
 Cisplatin+etoposide 169 (61.0)
 Carboplatin+etoposide 70 (25.3)
 Cisplatin+irinotecan 37 (13.4)
 Carboplatin+irinotecan 1 (0.4)
Second-line chemotherapy (n=155)
 Cisplatin+irinotecan 60 (38.7)
 Cisplatin+etoposide 21 (13.6)
 Irinotecan 19 (12.3)
 Topotecan or belotecan 17 (11.0)
 Carboplatin+etoposide 15 (9.7)
 Carboplatin+irinotecan 12 (7.7)
 Others 11 (7.1)
Exposure to cisplatin
 No 59 (21.3)
 Yes 218 (78.7)
No. of cisplatin cycles
 Median (interquartile range) 6 (5-7)
Cumulative cisplatin dose (mg/m2)
 Median (interquartile range) 420 (350-490)
Table 3.
Multivariate analysis of risk factors for development of thromboembolic events after start of chemotherapy
Variable Hazard ratio 95% Confidence interval p-value
Smoking statusa) 2.14 1.16-3.95 0.01
ACE-27 comorbiditya) 1.60 1.00-2.58 0.05
Superior vena cava invasion 2.25 0.91-5.57 0.08
 Limited 1 - -
 Extensive 2.19 1 0.97-4.95 0.06
 Non-cisplatin-based 1 - -
 Cisplatin-based 4.36 1.00-18.97 0.05

ACE, Adult Comorbidity Evaluation.

a) As the separate effects of ‘Smoking’ and ‘ACE-27 comorbidity’ (Table 1) did not provide a better model for the data, we assumed a linear trend in these variables which gives a more simple model, and displayed common hazard ratios from one group to the next.


1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22.
crossref pmid
2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.
crossref pmid
3. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822–9.
crossref pmid
4. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–64.
crossref pmid
5. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169–78.
crossref pmid
6. Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103:994–9.
crossref pmid
7. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466–73.
crossref pmid
8. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012;30:4416–26.
crossref pmid
9. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002;20:4665–72.
crossref pmid
10. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–5.
crossref pmid pmc
11. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.
crossref pmid
12. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.
crossref pmid pmc
13. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost. 2008;6:601–8.
crossref pmid
14. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6 Pt 1):2021–4.
crossref pmid
15. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007;5:2445–52.
crossref pmid
16. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs. 2008;19:927–9.
crossref pmid
17. Lu CF, Yu HJ, Hou JX, Zhou J. Increased procoagulant activity of red blood cells in the presence of cisplatin. Chin Med J (Engl). 2008;121:1775–80.
crossref pmid
18. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol. 1992;8:480–8.
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI